Skip to main content
. 2022 Aug 10;22:686. doi: 10.1186/s12879-022-07668-w

Table 2.

Incidence of primary and secondary outcomes in groups divided based on cutoff values

Trough < 13.94 μg/mL (n = 37) Trough ≥ 13.94 μg/mL (n = 28) Odds ratio p-value
30-day mortality 1 (2.7%) 8 (28.6%) 14.40 (1.68–123.56) 0.004
Treatment failure at EOT (n = 64)* 7 (19.4%) 8 (28.6%) 1.65 (0.51–5.30) 0.553
Nephrotoxicity (n = 63)** 3 (8.1%) 11 (39.3%) 7.33 (1.80–29.83) 0.005
90-day recurrence (n = 64)*** 4 (10.8%) 3 (11.1%) 1.08 (0.22–5.27) > 0.999
AUC24/MIC < 504 (n = 22) AUC24/MIC ≥ 504 (n = 43) Odds ratio p-value
30-day mortality 0 (0.0%) 9 (20.9%) N/A 0.023
Treatment failure at EOT (n = 64)* 3 (13.6%) 12 (27.9%) 2.23 (0.58–9.34) 0.348
Nephrotoxicity (n = 63)** 2 (9.1%) 12 (27.9%) 3.87 (0.78–19.15) 0.114
90-day recurrence (n = 64)*** 2 (9.1%) 5 (11.9%) 1.39 (0.25–7.82) > 0.999

EOT, end of treatment; ICU, intensive care unit; N/A: not applicable; MIC, minimum inhibitory concentration; AUC24, area under the curve during 24 h

*One patient whose treatment outcome was not assessable for having been referred to another hospital for the remaining treatment was excluded

**Two patients who were already in the ICU at the onset of bacteremia were not included

***One patient who died within 90 days without clearance of bacteremia was not included